CNTB

Connect Biopharma Holdings Limited American Depositary Shares (CNTB)

About Connect Biopharma Holdings Limited American Depositary Shares (CNTB)

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Details

Daily high

$1.38

Daily low

$1.29

Price at open

$1.40

52 Week High

$2.84

52 Week Low

$0.68

Market cap

77.4M

Dividend yield

0.00%

Volume

16,420

Avg. volume

26,950

P/E ratio

-.88

Connect Biopharma Holdings Limited American Depositary Shares News